We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

83 hedge funds and large institutions have $35.5M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 34 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

12% less funds holding

Funds holding: 94 → 83 (-11)

18% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 34

30% less capital invested

Capital invested by funds: $50.6M → $35.5M (-$15.1M)

58% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 19

Holders
83
Holders Change
-11
Holders Change %
-11.7%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
8
Increased
28
Reduced
34
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$923K
2
Renaissance Technologies
Renaissance Technologies
New York
+$206K
3
Deutsche Bank
Deutsche Bank
Germany
+$187K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$128K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$118K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$3.56M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.22M
3
BlackRock
BlackRock
New York
-$581K
4
BC
Boxer Capital
California
-$535K
5
JRP
Jasper Ridge Partners
California
-$250K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Column Group
California
$15.6M – – –
BlackRock
2
BlackRock
New York
$2.73M -$581K -661,714 -17%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.38M +$8.32K +9,472 +0.3%
EC
4
EcoR1 Capital
California
$2.05M -$3.56M -4,049,645 -63%
SG
5
StepStone Group
California
$1.35M – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$1.15M +$128K +145,360 +12%
Millennium Management
7
Millennium Management
New York
$1.08M +$923K +1,051,272 +498%
EC
8
Euclidean Capital
New York
$852K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$792K +$30.5K +34,709 +4%
State Street
10
State Street
Massachusetts
$706K +$24.5K +27,876 +4%
Renaissance Technologies
11
Renaissance Technologies
New York
$650K +$206K +234,565 +45%
N
12
Nuveen
North Carolina
$536K +$652 +742 +0.1%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$504K +$99.1K +112,900 +24%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$477K -$2.44K -2,778 -0.5%
Two Sigma Investments
15
Two Sigma Investments
New York
$421K +$73.5K +83,688 +21%
Federated Hermes
16
Federated Hermes
Pennsylvania
$297K -$211K -240,208 -41%
Northern Trust
17
Northern Trust
Illinois
$290K -$5.96K -6,789 -2%
GCP
18
GSA Capital Partners
United Kingdom
$287K +$106K +120,797 +57%
Morgan Stanley
19
Morgan Stanley
New York
$276K -$137K -156,318 -33%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$265K -$12.6K -14,368 -4%
Charles Schwab
21
Charles Schwab
California
$239K +$3.2K +3,640 +1%
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$190K +$118K +133,999 +155%
Deutsche Bank
23
Deutsche Bank
Germany
$183K +$187K +212,944 New
Squarepoint
24
Squarepoint
New York
$183K +$64.3K +73,257 +52%
BCM
25
Bridgeway Capital Management
Texas
$168K -$70.2K -80,000 -29%
1
2 3 4 5

NGM Hedge Fund Activity: Q4 2023 in Review

83 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2023, worth a combined $35.5M — down 30% from $50.6M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of NGM and 8 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 28 added.

The largest buyer was Millennium Management, adding an estimated $923K. The largest seller was EcoR1 Capital, cutting an estimated $3.56M.

  • 83 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2023, down from 94 in Q3 2023.
  • Funds reported $35.5M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2023, down 30% quarter-over-quarter.
  • 8 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2023 and 19 closed out, a net change of -11 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $923K added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2023 was EcoR1 Capital, an estimated $3.56M sold.

Based on aggregated 13F filings for Q4 2023.